IDEXX Q2 2026: Durable Momentum in Pet Diagnostics as EPS Rises and Revenue Outlook Tightens the Leash

Overview: A steady engine with a bigger lane to drive in

IDEXX Laboratories, Inc. reported its second‑quarter 2026 results, delivering a revenue beat in the sense of size and growth velocity rather than a one‑off surprise to a wall of consensus expectations. The company posted $1,217 million in quarterly revenue, up 10% from a year ago on a reported basis and 9% on an organic basis. The print highlights the resilience of its Technology for Life strategy, with continued strength across Diagnostics and related platforms.

On the earnings line, the company reported EPS of $4.27, an 18% increase year over year (up 15% on a comparable basis). The release notes tax benefits from share‑based compensation and currency changes contributing to the quarterly delta. The numbers are solid, but the narrative matters more: IDEXX frames the quarter as a continuation of durable, compounding growth rather than a one‑time upside.

Key Operational Highlights

• CAG Diagnostics recurring revenue grew 11% as reported and 10% organic, with international strength (~14% reported and 12% organic) and robust US performance.
• Instrument and service portfolio drove gains in utilization, with the IDEXX inVue Dx installed base surpassing 9,000 instruments and placements totaling more than 1,600 in the quarter.
• EPS drivers included the quarterly tax benefits from share‑based compensation and currency effects, contributing to the reported earnings uplift.
• Water and LPD revenue growth remained meaningful, underscoring broad mix advantages across the company’s portfolio.

Guidance and Outlook: Revenue forecast raised, margins and discipline intact

IDEXX raised its revenue forecast for 2026, narrowing the full‑year range to $4.7 billion to $4.745 billion, with the midpoint higher by about $5 million net of a roughly $15 million headwind from updated foreign exchange estimates. The company also lifted its revenue growth outlook midpoint to 9.7%, envisioning a 9.1%–10.3% range for 2026 growth.

The CAG Diagnostics recurring revenue trajectory remains the anchor, with a projected growth band of roughly 10.1%–11.3% for 2026 and organic growth in a similar high‑single‑digit range (roughly 9.5%–10.7% for organic). The company also updated its EPS outlook to a midpoint of roughly $14.69 to $14.94 for 2026, an increase of about $0.14 per share from prior guidance.

In short, management believes the ongoing adoption of IDEXX innovations—Catalyst, Fecal Dx, and IDEXX inVue Dx—along with an expanding installed base and favorable utilization trends, justifies a higher annual growth trajectory even as FX headwinds persist.

Strategic Context: What this says about IDEXX and the sector

The quarter fits a pattern of steady, durable growth in pet healthcare technology: a robust services ecosystem around diagnostics, recurring revenue streams, and a high‑margin instrument footprint gradually widening. The installed base growth for inVue Dx implies customers are continuing to invest in higher‑value diagnostics workflows, which should support recurring revenue and margin stability over time.

From a sector standpoint, IDEXX’s results underscore the value of a diversified product suite that balances instrument sales, consumables, and recurring diagnostics services. Peers watching this playbook may emphasize stronger international expansion, continued platform innovations, and disciplined capital allocation to sustain profitability amid FX and macro headwinds.

Analyst Lens: What this portends for the stock and peers

Readers should note that the press release does not explicitly publish an EPS consensus number or label the quarter as an earnings surprise against consensus. The reported results, however, reflect meaningful sequential and year‑over‑year improvement, suggesting the company is executing its plan well enough to support a higher revenue forecast and stepped‑up margin potential.

If the market treats this as confirmation of a durable growth trajectory, IDEXX could see a modest re‑rating, especially if foreign exchange pressures abate or the incremental demand from inVue Dx installations converts into more predictable, high‑quality revenue growth. For sector peers, the key takeaway is the ballast that comes from a diversified mix and a technology roadmap that translates installed assets into recurring value. Expect investors to scrutinize whether the 2026 organic growth targets are achievable given any residual FX drag and potential macro volatility.

Takeaways for Investors and the Road Ahead

• The quarterly print reinforces IDEXX’s core strength in diagnostics and instrument utilization, reinforcing the quality of its revenue forecast for 2026.
• EPS momentum is evident, but the lack of an explicit EPS consensus in the release means investors will rely on external estimates to gauge earnings surprise potential.
• Raising the 2026 guidance while highlighting FX headwinds points to a cautious optimism about accelerating growth from recurring revenue streams, particularly CAG Diagnostics.
• International expansion in Diagnostics remains a meaningful lever, with the potential for further upside as IDEXX extends its platform and service reach.